Under the terms of the Exclusive License, Radiance will pay CSPC an upfront payment of $15 million, and up to $150 million in potential development and regulatory milestone payments and over $1 ...

“We are excited to add RB-164, a promising clinical-stage Antibody Drug Conjugate targeting ROR-1, to our pipeline. This provides multiple shots on goal for potential therapeutic indications and ...

GU ASCO annual meeting featured a session on the ABCs of antibody drug conjugates and a presentation by Dr. Di Maria Jiang discussing the targeting of bladder cancer with antibody drug conjugates. Dr.

Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to ...

Another antibody drug conjugate disitamab vedotin (an anti-HER2 antibody drug conjugate with MMAE payload) has also been shown to potentially pair well with immunotherapy. Disitamab vedotin + ...

Ovarian cancer continues to pose a significant challenge in the medical field, remaining one of the leading causes of death ...

Ona Therapeutics ("Ona"), a global biotech company pioneering first-in-class antibody-drug conjugates (ADCs), today announced key ...

On-demand video webcast now available here BOSTON and LONDON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc ...

The theory behind antibody drug conjugates (ADCs ... If they fulfil the promise of “targeted” chemotherapy, they may displace classic chemotherapy in most cancer therapy cocktails.